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Herbal medicine hepatotoxicity revisited
Letters to the EditorTo the Editor:
In the April 2011 issue of the Journal of Hepatology, an editorial
discussed hepatotoxicity associated with the use of herbal prep-
arations [1]. The focus of the article is primarily on the need to
develop speciﬁc biomarkers for compounds or ingredients sus-
pected to be associated with hepatotoxicity in order to establish
clinical speciﬁcity when determining if a relationship exists
between an adverse event and the consumption of these agents.
We agree that identiﬁcation methods are crucial to product
safety and the industry continues to develop and validate identi-
ﬁcation methods for many commercialized ingredients. This issue
is also currently being addressed by the US Food and Drug
Administration (FDA) and various other regulatory agencies
worldwide. In the US, beginning in 2008, the FDA has enforced
the formal requirement for dietary supplement manufacturers
to comply with dietary supplement-speciﬁc Current Good Manu-
facturing Practices (cGMP) [2]. The regulations outline the
requirements that support product quality and safety including
ingredient testing, manufacturing equipment and facilities, man-
ufacturing process controls, product testing, product complaint
handling, and documentation. It is important to appreciate how
this higher level of scrutiny for dietary supplements allows for
better assurance against potential safety issues, including issues504 Journal of Hepatology 20related to contamination, adulteration, distribution, and safety
monitoring. It would be equally prudent to acknowledge that
since 2008, these manufacturing controls could mitigate ingredi-
ent contamination concerns that were suggested as the proposed
mechanisms involved with cases of liver injury associated with
these products. This article gives several examples of speciﬁc
ingredients alleged to have been associated with cases of liver
injury including references to Herbalife which is a brand, not a
single product or ingredient. The reference to Herbalife is also
somewhat immaterial in the context of the article’s discussion.
Herbalife has formally responded to this publication [3] to rebut
articles cited by these authors [4,5]. The articles were published
in 2007 and present case reports with dates of onset that range
from 1998 to 2004. These case reports involved a variety of food
and supplement products that are not representative of currently
marketed Herbalife products. Additionally, no toxic substance has
been identiﬁed as responsible for the liver reactions that were
alleged to have been associated with Herbalife products and none
of the suspect compounds listed by these authors are found in
any of Herbalife’s products. Although Herbalife uses green tea
extracts in its current products, all green tea extracts are water-
based extracts (equivalent to a hot tea infusion) that have never
been implicated in causing liver toxicity. Furthermore, since12 vol. 56 j 503–510
January 2005, Herbalife has met and cooperated with 25 regula-
tory agencies, including the Swiss BAG, to address liver-related
case reports and articles in the literature. None of the 25 agencies
has taken any regulatory action affecting Herbalife products.
Most recently, on December 22, 2010, Evira, the food safety
authority in Finland, closed its multi-year inquiry involving
Herbalife case reports, with the agency stating that all require-
ments were satisﬁed, and indicating Herbalife ‘‘acted properly’’
and in ‘‘a thorough manner’’ to ‘‘demonstrate its commitments
to food safety’’.
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Reply to: ‘‘Herbal medicine hepatotoxicity revisited’’
To the Editor:
The author’s letter states that the mention of some instances of
herbal medicines is immaterial in the context of the article’s dis-
cussion. We do not agree with this view for the following reasons.
The interest in biomarkers is particularly important for com-
plex herbal medicines and dietary supplements with reports of
hepatotoxicity. Herbalife is one, well illustrated example, which
is supported by at least six peer-review publications [1–6] and a
recent review gathering no less than 30 cases [7]. The causality of
several products sold under the brand name «Herbalife» has
been assessed by using internationally recognized criteria
(WHO score, RUCAM) and has been analysed as certain (positive
rechallenge) or probable in a large number of these cases [1–7].
We appreciate that the manufacturer has made great efforts
to cooperate with health agencies and to produce the safest pos-
sible product.
The fact that the manufacturer did not identify toxic products
does not exclude the role of a particular component or an unex-
pected contaminating product in the overall preparation, particu-
larly when the composition is fairly complex. Furthermore, there
are numerous examples of «classical» drugs associated with very
well documented cases of liver idiosyncratic reactions in a small
proportion of subjects, for which extensive toxicological studies
did not disclose any speciﬁc risk [8]. So, an idiosyncratic reaction
with one of the components of Herbalife is a reasonable
possibility.
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